Thyrocare Technologies · NSE: THYROCARE · BSE: 539871

Q1 FY26 results · Apr–Jun 2025

Thyrocare Technologies reported revenue from operations of ₹193.03 crore (up 23.0% from Q1 FY25) and net profit of ₹38.29 crore (up 59.9% from Q1 FY25) for Q1 FY26 (Apr–Jun 2025), on a consolidated basis.

Consolidated · ₹ crore
Item	Q1 FY26	Q1 FY25	YoY	Q4 FY25	QoQ
Revenue from operations	193.03	156.91	+23.0%	187.16	+3.1%
Other income	4.65	3.62	+28.5%	4.59	+1.3%
Total income	197.68	160.53	+23.1%	191.75	+3.1%
Profit before share of associates & JVs and tax	50.23	33.91	+48.1%	47.82	+5.0%
Share of profit/(loss) of associates & JVs	0.25	(0.36)		(0.63)
Net profit for the period	38.29	23.94	+59.9%	21.57	+77.5%
Attributable to shareholders of the company	38.93	24.17	+61.1%	21.70	+79.4%
EPS, basic (₹)	7.35	4.52	+62.6%	4.17	+76.3%
Net margin (%)	19.8	15.3		11.5

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q1 FY26	Q1 FY25	YoY	Q4 FY25	QoQ
Revenue from operations	178.89	143.63	+24.5%	173.87	+2.9%
Other income	3.96	3.17	+24.9%	4.54	−12.8%
Total income	182.85	146.80	+24.6%	178.41	+2.5%
Profit before tax	50.91	35.14	+44.9%	47.80	+6.5%
Net profit for the period	36.05	25.15	+43.3%	21.95	+64.2%
EPS, basic (₹)	6.80	4.75	+43.2%	4.08	+66.7%
Net margin (%)	20.2	17.5		12.6

Consolidated

Filed with BSE: 23 Jul 2025, 18:20 IST
Board meeting: 23 Jul 2025
Period: 01 Apr 2025 to 30 Jun 2025
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 23 Jul 2025, 18:20 IST
Board meeting: 23 Jul 2025
Period: 01 Apr 2025 to 30 Jun 2025
Review status: Unaudited
Source: XBRL filing on BSE